title: Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma.
authors.forename: Didier
authors.initials: D
authors.lastname: Decaudin
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Etienne
authors.forename: Patricia
authors.initials: P
authors.lastname: De Cremoux
authors.forename: Zofia
authors.initials: Z
authors.lastname: Maciorowski
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Vantelon
authors.forename: Eric
authors.initials: E
authors.lastname: Voog
authors.forename: SaIk
authors.initials: S
authors.lastname: Urien
authors.forename: Carine
authors.initials: C
authors.lastname: Tran-Perennou
authors.forename: Nicole
authors.initials: N
authors.lastname: Renée
authors.forename: Philippe
authors.initials: P
authors.lastname: Vielh
authors.forename: Fariba
authors.initials: F
authors.lastname: Némati
authors.forename: Pierre
authors.initials: P
authors.lastname: Pouillart
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D004334:Drug Administration Schedule; D020847:Estrogen Receptor Modulators / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D005240:Feasibility Studies; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D013629:Tamoxifen / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D020847:Estrogen Receptor Modulators; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen